SCHEMBL25371880

SCHEMBL25371880

Cn1nc(C(F)(F)F)cc1S(=O)(=O)N1CC2(CN(C3CCOCC3)C2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 1/20 0.37
▸ TGFBR1 P36897 3/20 0.34
▸ HPGD P15428 1/20 0.33
▸ PTGS2 P35354 1/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ PSEN1 P49768 1/20 0.30
▸ PSEN2 P49810 1/20 0.30
▸ APH1B Q8WW43 1/20 0.30
▸ NCSTN Q92542 1/20 0.30
▸ APH1A Q96BI3 1/20 0.30
▸ PSENEN Q9NZ42 1/20 0.30
▸ CNR2 P34972 1/20 0.30
▸ CHRM2 P08172 1/20 0.30
▸ CHRM4 P08173 1/20 0.30
▸ CHRM5 P08912 1/20 0.30
▸ CHRM1 P11229 1/20 0.30
▸ CHRM3 P20309 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25372914 0.93 HPGD (0.32) CTSKHPGDMEN1KMT2ACNR2
SCHEMBL25370768 0.92 CTSK (0.37) CTSKTGFBR1HPGDMEN1KMT2A
SCHEMBL25370750 0.92 CTSK (0.37) CTSKTGFBR1HPGDMEN1KMT2A
SCHEMBL25370553 0.88 CTSK (0.37) CTSKHPGDMEN1KMT2AKCNH2
SCHEMBL27346368 0.86 CTSK (0.39) CTSKTGFBR1HPGDPTGS2MEN1
SCHEMBL26064882 0.86 MEN1 (0.39) CTSKHPGDMEN1KMT2ADDR1
SCHEMBL27346508 0.86 CTSK (0.39) CTSKTGFBR1HPGDPTGS2MEN1
SCHEMBL25369931 0.85 EBP (0.38) CTSKPTGS2PSEN1PSEN2APH1B
SCHEMBL27034404 0.84 CTSK (0.37) CTSKNPC1RAB9A
SCHEMBL27034397 0.84 CTSK (0.37) CTSKHPGDMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 — — US claimed
EP-4482587-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-01-01 — — EP claimed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 — — WO claimed
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 — — US disclosed
EP-4482587-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-01-01 — — EP disclosed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP CTSK 4031/4885TGFBR1 2833/4885HPGD 2721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback